MorphoSys AG / Key phrase(s): Change in Forecast
Advert-hoc: MorphoSys AG to replace monetary steerage for 2021 and scale back monetary liabilities
26-Jul-2021 / 13:05 CET/CEST
Disclosure of an inside info acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP – a service of EQS Group AG.
The issuer is solely chargeable for the content material of this announcement.
Publication of an inside info in keeping with Article 17 para. 1 of the Regulation (EU) No 596/2014
Planegg/Munich, Germany, July 26, 2021
Advert hoc: MorphoSys AG to replace monetary steerage for 2021 and scale back monetary liabilities
MorphoSys AG (FSE: MOR; NASDAQ: MOR) publicizes as we speak an replace of its monetary steerage for 2021 after preliminary completion of the newest analysis of MorphoSys’ half yr 2021 monetary efficiency.
Primarily based on the preliminary unaudited consolidated outcomes for the primary six months 2021, MorphoSys now expects Group revenues within the vary of € 155 to € 180 million (beforehand: € 150 to € 200 million, supplied on March 15, 2021 and reiterated on Could 5, 2021). The up to date income steerage primarily displays up to date Monjuvi(R) product gross sales expectations.
MorphoSys now expects Group working bills, which is comprised of R&D and Promoting, in addition to Common & Administrative bills, within the vary of € 435 to € 465 million (beforehand: € 355 to € 385 million). R&D bills now are anticipated to comprise 52 to 57% of Group working bills (beforehand 45-50%), excluding one-time transaction-related prices. The up to date steerage for Group working bills primarily displays the acquisition of Constellation Prescription drugs (Constellation), which was accomplished on July 15, 2021. The revised Group vary additionally consists of one-time transaction prices of € 36 million, associated to the agreements with Constellation and Royalty Pharma.
Because of the up to date Monjuvi product gross sales expectations, the steadiness sheet place “Monetary Liabilities from Collaborations, Web of Present Portion” is decreased from € 547.6 million (steadiness as of March 31, 2021) to € 445.9 million (steadiness as of June 30, 2021). The steadiness in “Monetary Liabilities from Collaborations, Web of Present Portion”, displays an accounting view of anticipated income from the online product gross sales of Monjuvi within the U.S. within the r/r DLBCL setting owed to our accomplice Incyte. The discount in Monetary Liabilities from Collaborations has no affect to money.
Full outcomes will likely be printed as deliberate on July 28, 2021.
END OF AD HOC RELEASE
Info and Clarification of the Issuer to this Information:
MorphoSys (FSE & NASDAQ: MOR) is a biopharmaceutical firm devoted to the invention, growth and commercialization of revolutionary therapies for individuals dwelling with most cancers and autoimmune ailments. Primarily based on its main experience in antibody and protein applied sciences, MorphoSys is advancing its personal pipeline of recent drug candidates and has created antibodies which might be developed by companions in several areas of unmet medical want. In 2017, Tremfya(R) (guselkumab) – developed by Janssen Analysis & Growth, LLC and marketed by Janssen Biotech, Inc. for the therapy of plaque psoriasis – turned the primary drug primarily based on MorphoSys’ antibody know-how to obtain regulatory approval. In July 2020, the U.S. Meals and Drug Administration granted accelerated approval of the corporate’s proprietary product Monjuvi(R) (tafasitamab-cxix) together with lenalidomide for sufferers with a sure kind of lymphoma. Headquartered close to Munich, Germany, the MorphoSys Group, together with the absolutely owned U.S. subsidiaries MorphoSys US Inc. and Constellation Prescription drugs, Inc., has greater than 750 staff. For extra info go to www.morphosys.com.
Monjuvi(R) is a registered trademark of MorphoSys AG.
Tremfya(R) is a registered trademark of Janssen Biotech, Inc.
Ahead Trying Statements
This communication incorporates sure forward-looking statements regarding the MorphoSys group of firms. The forward-looking statements contained herein signify the judgment of MorphoSys as of the date of this launch and contain identified and unknown dangers and uncertainties, which could trigger the precise outcomes, monetary situation and liquidity, efficiency or achievements of MorphoSys, or trade outcomes, to be materially totally different from any historic or future outcomes, monetary circumstances and liquidity, efficiency or achievements expressed or implied by such forward-looking statements. As well as, even when MorphoSys’ outcomes, efficiency, monetary situation and liquidity, and the event of the trade by which it operates are per such forward-looking statements, they might not be predictive of outcomes or developments in future durations. Among the many elements which will lead to variations are that MorphoSys’ expectations could also be incorrect, the inherent uncertainties related to aggressive developments, medical trial and product growth actions and regulatory approval necessities, MorphoSys’ reliance on collaborations with third events, estimating the business potential of its growth applications and different dangers indicated within the threat elements included in MorphoSys’ Annual Report on Type 20-F and different filings with the U.S. Securities and Trade Fee. Given these uncertainties, the reader is suggested to not place any undue reliance on such forward-looking statements. These forward-looking statements communicate solely as of the date of publication of this doc. MorphoSys expressly disclaims any obligation to replace any such forward-looking statements on this doc to replicate any change in its expectations with regard thereto or any change in occasions, circumstances or circumstances on which any such assertion is predicated or which will have an effect on the chance that precise outcomes will differ from these set forth within the forward-looking statements, until particularly required by regulation or regulation.
For extra info, please contact:
Dr. Julia Neugebauer
Senior Director Investor Relations
Tel: +49 (0)89 / 899 27 179
Senior Director Investor Relations
Tel: +1 857-772-0240
26-Jul-2021 CET/CEST The DGAP Distribution Providers embrace Regulatory Bulletins, Monetary/Company Information and Press Releases.
Archive at www.dgap.de